Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 10/20 | 0.74 |
| ▸ | CTSS | P25774 | 5/20 | 0.74 |
| ▸ | CTSK | P43235 | 5/20 | 0.74 |
| ▸ | CTSB | P07858 | 5/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.59 |
| ▸ | CTSV | O60911 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28714613 | 0.88 | CTSL (0.71) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL3498845 | 0.88 | CTSL (0.71) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL27520440 | 0.86 | CTSL (0.68) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL7417163 | 0.86 | CTSL (0.68) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL5517755 | 0.85 | CTSL (1.00) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL6021768 | 0.85 | CTSL (1.00) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL13956888 | 0.84 | CTSL (0.70) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL4357736 | 0.84 | ACE (0.68) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL29228939 | 0.84 | CTSL (0.66) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL4356229 | 0.84 | ACE (0.68) | CTSLCTSSCTSKCTSBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207107-B2 | Di-amido gellant for use in consumer product compositions | THE PROCTER & GAMBLE COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8168579-B2 | Fluid detergent compositions comprising a di-amido gellant, and processes for making | THE PROCTER AND GAMBLE COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110224455-A1 | Di-Amido Gellant For Use In Consumer Product Compositions | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
| US-20110220536-A1 | Fluid Detergent Compositions Comprising a Di-Amido Gellant, and Processes for Making | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224455-A1 | Di-Amido Gellant For Use In Consumer Product Compositions | DAGLA, GNPAT, CDIPT | CTSL 4507/4885CTSS 4321/4885CTSK 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.